JP2008536855A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536855A5
JP2008536855A5 JP2008506671A JP2008506671A JP2008536855A5 JP 2008536855 A5 JP2008536855 A5 JP 2008536855A5 JP 2008506671 A JP2008506671 A JP 2008506671A JP 2008506671 A JP2008506671 A JP 2008506671A JP 2008536855 A5 JP2008536855 A5 JP 2008536855A5
Authority
JP
Japan
Prior art keywords
medicament
antibody
medicament according
ibd
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008506671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013780 external-priority patent/WO2006113308A1/en
Publication of JP2008536855A publication Critical patent/JP2008536855A/ja
Publication of JP2008536855A5 publication Critical patent/JP2008536855A5/ja
Withdrawn legal-status Critical Current

Links

JP2008506671A 2005-04-15 2006-04-13 炎症性腸疾患（ｉｂｄ）の治療 Withdrawn JP2008536855A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67190205P 2005-04-15 2005-04-15
PCT/US2006/013780 WO2006113308A1 (en) 2005-04-15 2006-04-13 Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody

Publications (2)

Publication Number Publication Date
JP2008536855A JP2008536855A (ja) 2008-09-11
JP2008536855A5 true JP2008536855A5 (enExample) 2009-05-28

Family

ID=36685736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506671A Withdrawn JP2008536855A (ja) 2005-04-15 2006-04-13 炎症性腸疾患（ｉｂｄ）の治療

Country Status (16)

Country Link
US (1) US20060233797A1 (enExample)
EP (1) EP1871414A1 (enExample)
JP (1) JP2008536855A (enExample)
KR (1) KR20070122543A (enExample)
CN (1) CN101184507A (enExample)
AR (1) AR053579A1 (enExample)
AU (1) AU2006236816A1 (enExample)
BR (1) BRPI0612321A2 (enExample)
CA (1) CA2605020A1 (enExample)
IL (1) IL186151A0 (enExample)
MX (1) MX2007012667A (enExample)
NO (1) NO20075845L (enExample)
RU (1) RU2007142188A (enExample)
TW (1) TW200714291A (enExample)
WO (1) WO2006113308A1 (enExample)
ZA (1) ZA200708850B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
WO2009018411A1 (en) * 2007-07-31 2009-02-05 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
EP2262509A4 (en) * 2008-03-07 2012-02-22 Lawrence Bernstein GALLIUM COMPOUNDS AND METHOD OF USE FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2288719A4 (en) * 2008-05-15 2012-01-11 Univ Tufts METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
WO2013090989A1 (en) * 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN103149371B (zh) * 2013-02-26 2015-12-23 哈药慈航制药股份有限公司 生物标记物在制备预测5-氨基水杨酸治疗溃疡性结肠炎的反馈响应药物中的应用
SI3054996T1 (sl) 2013-10-07 2023-11-30 Igl Pharma, Inc. Postopek za pripravo terapevtskih sredstev za kosti visoke čistote
US10435475B2 (en) * 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
EP3606542A4 (en) * 2017-04-07 2021-01-20 Second Genome, Inc. PROTEINS FOR THE TREATMENT OF DISORDERS OF THE EPITHELIAL BARRIER FUNCTION
WO2019018440A1 (en) 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
US20220091135A1 (en) * 2019-01-04 2022-03-24 Kyoto University Test method for ulcerative colitis and primary sclerosing cholangitis
WO2021110127A1 (en) * 2019-12-06 2021-06-10 Cheer Global Limited Method of treating inflammatory bowel disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
TR200101302T2 (tr) * 1998-11-09 2001-10-22 Idec Pharmaceuticals Corporation BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
IL151906A0 (en) * 2000-03-24 2003-04-10 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
DK1272647T3 (en) * 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2002078766A2 (en) * 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
HRP20090325T1 (en) * 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
CN1860367B (zh) * 2003-07-29 2010-05-26 健泰科生物技术公司 人抗cd20抗体的测定法及其用途
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
ZA200601218B (en) * 2003-08-29 2007-05-30 Genentech Inc Anti-CD20 therapy of ocular disorders
CA2549122A1 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in therapy of autoimmune diseases
BRPI0510224A (pt) * 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Similar Documents

Publication Publication Date Title
JP2008536855A5 (enExample)
Tanida et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease
Benchimol et al. Traditional corticosteroids for induction of remission in Crohn's disease
Yamamoto et al. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn’s disease
Serrano et al. Use of infliximab in pediatric patients with inflammatory bowel disease
RU2007142188A (ru) Способ лечения воспалительного заболевания кишечника (взк) анти-cd-20 антителом
EP4212160A1 (en) Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy
EP2968309A2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
McCormack et al. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
Zavaleta-Monestel et al. Advances in systemic lupus erythematosus treatment with monoclonal antibodies: a mini-review
JP2021522345A (ja) 新規なｍｃｔ４阻害剤及びその使用
Actis et al. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease
JPWO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
Panahi et al. Hepatotoxicity secondary to levofloxacin use
TWI768263B (zh) 西達本胺聯合r-chop的應用及聯合藥物
CN110831590A (zh) 含有培马贝特的医药
Baldwin et al. Managing pediatric Crohn’s disease: recent insights
Ebied et al. 2017 is banner year for drug approvals by the Food and Drug Administration
EP4616867A1 (en) Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy
JP6802598B1 (ja) 抗がん剤の効果増強剤
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
CN102389564A (zh) 用于治疗骨髓增生异常综合征的组合物和方法及用途
CN113425723B (zh) Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用
RU2802620C2 (ru) Применение хидамида в комбинации с R-CHOP и комбинация лекарственных средств
Magno et al. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn’s disease